Related references
Note: Only part of the references are listed.A phase I study of visilizumab a humanized anti-CD3, monoclonal antibody, in severe steroid-refractory ulcerative colitis
Scott Plevy et al.
GASTROENTEROLOGY (2007)
Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies
Daniel C. Baumgart et al.
LANCET (2007)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Transforming growth factor-β induces development of the TH17 lineage
PR Mangan et al.
NATURE (2006)
Effect of adenosine A2A receptor activation in murine models of respiratory disorders
O Bonneau et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy
AS Awad et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938
M Kuno et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
LE Harrington et al.
NATURE IMMUNOLOGY (2005)
A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis
G Gallos et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis
R Bibiloni et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease
M Odashima et al.
GASTROENTEROLOGY (2005)
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD
J Ermann et al.
BLOOD (2005)
Trichuris suis therapy in Crohn's disease
RW Summers et al.
GUT (2005)
CD4(+) CD25(+) CD62(+) T-regulatory cell subset has optimal suppressive and proliferative potential
S Fu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells
S Yamazaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The immunological and genetic basis of inflammatory bowel disease
G Bouma et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome
WR Law et al.
CRITICAL CARE MEDICINE (2003)
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis
J Mabley et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Rapid development of colitis in NSAID-treated IL-10-deficient mice
DJ Berg et al.
GASTROENTEROLOGY (2002)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behcet's disease
K Köse et al.
CLINICAL BIOCHEMISTRY (2001)
Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus
S Hitoglou et al.
CLINICAL RHEUMATOLOGY (2001)
Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms
G Haskó et al.
FASEB JOURNAL (2000)
Share Paper
